Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 11, 1997

View Archived Issues

Company Profile: Cell Therapeutics

Synsorb Biotech: nine-month 1997 highlights

British Biotech: Q2 and HY 1997/98 highlights

Inex: Q3 1997 highlights

ImClone Systems' C225 enters phase II for metastatic renal cell carcinoma

Algene: Q3 1997 highlights

Protein farnesyltransferase inhibitors focus of research at Merck & Co.

3-Dimensional Pharmaceuticals discloses new serine protease inhibitors

Agents for HCV infection from ViroPharma

Novel antithrombotic agent developed at Otsuka

Potential new male contraceptive under development in China

E-5531: a synthetic endotoxin antagonist developed at Eisai

Preclinical and preliminary clinical profile of NE-100, a new antipsychotic drug

Potent and selective dopamine D4 antagonist discovered at Yamanouchi

Yamanouchi describes SAR leading to YM-60828, a potent and selective factor Xa inhibitor

Profile of novel topoisomerase II inhibitor, ER-37328, from Eisai

SAR and biological profile of FR-86521, a cephalosporin highly active against MRSA

Meiji Seika presents new carbapenem derivatives

MKT-077: a novel antitumor rhodacyanine dye in clinical testing

Fujisawa discovers new triazole antifungals with excellent oral activity

New indication for Neutralase revealed

FDA approves SERM for preventing postmenopausal osteoporosis

Integrilin to be reviewed by FDA advisory panel

Cel-Sci AIDS vaccine effective in mouse model of HIV and immunogenic in humans

FDA approves Neoprobe's IND for RIGS/ACT therapy

Emisphere and Novartis sign agreement for drug delivery research

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...